PRNewsWire
29 May 2026, 05:01 UTC · 15h ago
Source · https://www.prnewswire.com/news-releases/pepromene-bio-anuncia-una-presentacion-oral-en-eha-2026-donde-destacara-el-pmb-ct01-en-linfomas-de-celulas-b-302785315.html
Read source
Search tags
Story key points
5 claims · impact-rated
PMB-CT01 achieved a 78% complete response rate (7 out of 9 patients) in a Phase 1 dose-escalation study for B-cell non-Hodgkin lymphoma. — A high complete response rate in a Phase 1 trial is a strong signal of efficacy for a novel oncology candidate.
+0.80PMB-CT01 demonstrated efficacy in patients who had previously failed standard CD19-targeted CAR T-cell therapy, including a complete remission in a transformed follicular lymphoma patient. — Addressing an unmet need in patients refractory to current gold-standard CAR-T therapies expands the potential market and therapeutic value.
+0.70The therapy showed a favorable safety profile with no dose-limiting toxicities and no Grade >1 cytokine release syndrome (CRS) or neurotoxicity (ICANS). — Reduced toxicity compared to typical CAR-T therapies could enable outpatient administration and broaden the patient population.
+0.60Continue reading
6 related stories
PeproMene Bio is actively recruiting patients for expansion cohorts in mantle cell lymphoma, large B-cell lymphoma, and follicular lymphoma. — Progression into expansion cohorts indicates clinical confidence and moves the drug closer to pivotal trial stages.
+0.40The company plans to present updated clinical data orally at the 2026 European Hematology Association (EHA) Congress on June 14. — Oral presentations at major medical congresses provide visibility and can act as a catalyst for investor interest.
+0.20Ticker attribution
Model heads
No ticker sentiment head found.
No ticker relationship head found.
Impact vectors
3 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Zacks Investment Research
1d ago
